Hikma to invest $1 billion in U.S. manufacturing expansion, strengthening Ohio’s role in medicine production
Image: Hikma Pharmaceuticals ground breaking in Columbus
Hikma Pharmaceuticals USA has announced a $1 billion investment to expand its U.S.-based manufacturing and R&D footprint, with major implications for Ohio’s growing role in domestic medicine production.
The company’s continued investment reinforces national efforts to strengthen pharmaceutical supply chains and reduce reliance on foreign-made drugs.
The big picture
Hikma has operated in the U.S. for over 30 years and currently produces more than 12 billion doses of essential generic medicines annually. The new expansion—branded America Leans on Hikma—includes its facilities in Columbus and Cleveland, Ohio, as well as locations in New Jersey.
The $1 billion commitment through 2030 will:
Expand production of sterile injectable and essential medicines
Enhance domestic research and development
Bolster Hikma’s portfolio of more than 800 generic products
Ohio spotlight
The announcement was made at a groundbreaking event at Hikma’s state-of-the-art Columbus facility, with U.S. Rep. Mike Carey (OH-15) in attendance. Carey praised the company’s ongoing investment in the region and its impact on job creation and health security.
“Hikma continues to invest in American workers and I am thrilled that they have chosen to continue that commitment here in Columbus,” said Rep. Carey. This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans’ access to high-quality, affordable medicines.”
Hikma's Ohio operations have become increasingly vital to the company’s U.S. growth strategy. In addition to Columbus, Hikma maintains a presence in Cleveland, positioning Ohio as a major pharmaceutical manufacturing hub.
National implications
Hikma is now the third-largest supplier of sterile injectable medicines in the U.S. With growing concerns over drug shortages and global supply chain disruptions, the company’s expansion supports broader national goals to reshore pharmaceutical manufacturing.
“It’s important that we onshore the production of these critical drugs,” said Rep. Buddy Carter (GA-01), a pharmacist and Chair of the American-Made Medicines Caucus.
What’s next
Hikma plans to use this next phase of investment to increase U.S. capacity, enhance drug availability, and support a more resilient pharmaceutical ecosystem—powered by American workers and infrastructure.